Dermata Therapeutics chairman and CEO Gerald Proehl takes Proactive’s Stephen Gunnion through the clinical-stage biotechnology company’s pipeline of treatments focused on medical and aesthetic skin conditions.
He says the company’s lead candidate DMT310 will move into Phase 3 studies once it gets the go-ahead from the US Food and Drug Administration (FDA) – a major milestone for Dermata. The acne treatment is the first product candidate being developed from the company’s Spongilla technology platform.
DMT410 uses its Spongilla technology as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions.
#ProactiveInvestors #DermataTherapeutics #nasdaq #Dermatology #Skincare #AcneTreatment #NaturalRemedies #OnceAWeekApplication #DMT310 #DMT410 #BotulinumToxin #ClinicalTrials #Phase3Studies #FDAApproval #BiotechInvesting #SkinHealth #BeautyCare #HealthySkin #MedicalResearch #TopicalApplications #AntiInflammatory #AntiMicrobial #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
source